Anti-Influenza Neutralizing Antibody

Dear Colleagues,

The history of Influenza viral infection is a nefarious one. With its first pandemic of the early 1900s, arguably responsible for the death of 40 million people worldwide, the morbidity and mortality it has caused for over the better part of a century has indelibly marked its status as a formidable pathogen. The variations encountered over time, including, but not limited to, Asian, Hong Kong, Avian, and the recent H1N1 types, continue to pose a constant threat to society. This has spurred entities such as the World Health Organization to develop pandemic preparedness plans designed to effectively respond to pandemic illness. In addition, further understanding of the biological processes involved in the pathogenesis, as well as protective mechanisms of influenza, have also been actively pursued.

Neutralizing antibodies have been employed as means of mitigating viral infections either alone or in conjunction with synergistic effects of humoral and cellular arms of the immune system. Anti- hemaglutinin and anti-neuraminidase antibodies have been reported with some success in influenza viral infection of varying types (H5 N1, H1 N1, etc.) either alone or with other chemical or immune system potentiation.

This Special Issue of Antibodies focuses on anti-influenza neutralizing antibodies towards elucidating the role, function, mechanisms as either independent stand alone therapy or in conjunction with potentiation with other augmenting mediators of the immune system, and—rather importantly—their clinical application to human disease. The culmination of such progress holds promise toward obviating the spread and deleterious sequelae of this devastating disease.

Dr. Martin H. Bluth
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• influenza
• neutralizing
• antibodies
• virus
• strains
• humoral
• cellular
• immunology
• immunotherapy